Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Discov. Author manuscript; available in PMC 2013 May 1.
Published in final edited form as:
PMCID: PMC3384541

Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anti-cancer agent


Genetic approaches have demonstrated that the p110β isoform of PI3K is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collection of compounds possessing activities against kinases in the PI3K superfamily and identified a potent and selective p110β inhibitor: KIN-193. We show that KIN-193 is efficacious specifically in blocking AKT signaling and tumor growth that are dependent on p110β activation or PTEN-loss. Broad profiling across a panel of 422 human tumor cell lines demonstrates that the PTEN mutation status of cancer cells strongly correlates with their response to KIN-193. Together, our data provide the first pharmacological evidence that PTEN-deficient tumors are dependent on p110β in animals, and suggest that KIN-193 can be pursued as a drug to treat tumors that are dependent on p110β, while sparing other PI3K isoforms.


The class Ia phosphatidylinositol-3-kinase (PI3K) pathway is arguably the most important signaling pathway in cells because of its roles in the control of cell growth, survival and death(1, 2). The PI3K pathway is activated at the cell membrane by an important lipid signaling molecule known as phosphatidylinositol 3,4,5-trisphosphate (PIP3). Under normal conditions, the level of PIP3 is tightly regulated by the activities of two enzymes, PI3K (a lipid kinase) and PTEN (a lipid phosphatase), which act as “on/off” switches in opposition to each other. In response to the extracellular signals mediated by receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs), or GTPases, class Ia PI3Ks are recruited to the cell membrane and subsequently phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to produce PIP3. This in turn activates the Ser/Thr kinase AKT and other downstream effectors to regulate multiple cellular functions, including proliferation, survival and migration. Class Ia PI3Ks are heterodimeric lipid kinases consisting of a p110 catalytic subunit (p110α, p110β, or p110δ) and a p85 regulatory subunit. While the expression of p110δ is largely restricted to the immune system, p110α and p110β are commonly expressed in all tissues. The tumor suppressor PTEN catalyzes the dephosphorylation of PIP3 back to PIP2 and thereby antagonizing PI3K activity.

Aberrant activation of the class Ia PI3K signaling pathway is a common event in many types of cancer. Frequently observed mechanisms of PI3K pathway hyperactivation include gain-of-function mutations in p110α, loss-of-function mutations or deletions in PTEN, and activation of RTKs (2). No activating mutations have been found in p110β so far, with the exception of gene amplification in breast and ovarian cancers (3, 4). Interestingly, however, we have recently found that genetic ablation of p110β, but not p110α, is sufficient to inhibit tumor formation driven by Pten loss in the anterior prostate in a mouse prostate tumor model (5). Other recent studies have demonstrated that certain PTEN-deficient human cancer cell lines are sensitive to inactivation of p110β rather than p110α (6, 7).

In order to investigate whether the dependence on p110β can be recapitulated with pharmacological inhibitors of p110β kinase activity, several groups have been developing p110β specific inhibitors. However, only a few selective p110β inhibitors have been reported. Perhaps the best described p110β-specific inhibitor to date is TGX-221 that has been used in defining p110β as an important new target for antithrombotic agent (8), but none of these compounds have been reported for tumor studies in vivo. We sought to identify alternative compounds that are potent and selective p110β inhibitors with properties suitable for use in tumor studies in vivo. Here we demonstrate that KIN-193 is a potent and selective p110β inhibitor, when evaluated in a battery of biochemical and cellular assays. In addition, we show that this compound can inhibit the growth of tumors driven by p110β or PTEN-loss in vivo. Together, this study has identified and characterized KIN-193 as a potential antitumor agent that can be used to treat tumors that are dependent on p110β, while sparing other PI3K isoforms.


In order to screen for new selective PI3Kβ inhibitors, we generated a set of isogenic human mammary epithelial cells (HMEC) lines that stably express myristolyated (Myr)-tagged PI3K class Ia p110 isoforms (p110α, p110β, or p110δ), respectively, designated as HMEC-CA-p110α, HMEC-CA-p110β, and HMEC-CA-p110δ. In these cell lines, endogenous PI3K signaling is inactive under serum-free condition, whereas the ectopically expressed Myr-p110 isoforms are membrane targeted and constitutively active due to N-terminal myristoylation (9, 10), thus driving the phosphorylation of AKT, a downstream target of PI3K (Supplementary Fig. S1, first lane vs. second lane). Notably, activation of p110α can also be achieved by N-terminal addition (11). We validated the specificity of this system by monitoring the ability of well-characterized p110 isoform-specific inhibitors, e.g. PIK-75 for p110α (12), TGX-221 for p110β (8), IC87114 for p110δ (13), and a pan inhibitor GDC-0941(14), to inhibit phosphorylation of AKT at both Thr308 and Ser473 in a dose-dependent manner (Supplementary Fig. S1).

The high degree of sequence similarity among p110 catalytic isoforms of PI3K makes it extremely challenging to develop isoform-specific PI3K inhibitors de novo(15), we therefore assembled a collection of 19 compounds possessing activity against PI3Ks (Supplementary Table 1) for our study. To facilitate systematic analyses of these compounds, we used the BacMam gene delivery technology to express GFP-AKT in these isogenic HMEC cells which enables a time-resolved fluorescence resonance energy transfer (TR-FRET) based assay termed ‘LanthaScreen’ (16). The phosphorylation status of AKT at both Thr308 and Ser473 was measured by the binding of terbium-labeled phospho-specific antibodies that undergo FRET with the GFP labeled AKT (Supplementary Fig. S2A). The most promising candidate to emerge from this profiling was KIN-193 (Fig. 1A and Supplementary Fig. S2B), a compound recently described as a p110β-selective inhibitor (17). Interestingly, KIN-193 is a close structural analog of TGX-221, a p110β isoform-specific inhibitor that has been used in defining p110β as an important new target for antithrombotic agent (8) (Fig. 1B). KIN-193 has comparable selectivity and potency against p110β compared to TGX-221 as measured by AKT phosphorylation in HMECs via Western blot analysis (Supplementary Fig. S3).

Figure 1
Identification of KIN-193 as a p110β specific inhibitor. A, Distribution of IC50 values for selected small molecule inhibitors against various PI3K p110 isoforms in isogenic HMEC lines expressing CA-p110α, CA-p110β, or CA-p110δ ...

We next determined the target spectrum of KIN-193 against PI3K superfamily as well as the kinome. An in vitro kinase assay demonstrated that KIN-193 is highly potent in the inhibition of p110β’s kinase activity (IC50 of 0.69 nM) and has 200, 20, and 70-fold selectivity over p110α, p110δ, and p110γ isoforms, respectively (Fig. 1C). KIN-193 also exhibited selectivity of ~80 fold over PI3K-C2β and DNA-PK and more than 1,000-fold over other phosphatidylinositol-3 kinase–related kinases (PIKKs) (Fig. 1C). An inhibitor-kinase interaction profiling of KIN-193 against a panel of 433 kinases using the KinomeScan approach (DiscoverX) demonstrated that KIN-193 is highly selective in its interaction with PI3Ks (Fig. 1D and Supplementary Table 2). Together, these data suggest that KIN-193 is a selective kinase inhibitor that targets the p110β isoform of PI3K.

Recent studies have shown that certain PTEN-deficient tumors are critically dependent on p110β activity (57). To determine whether KIN-193 selectively targets PTEN-deficient tumors, we tested the effect of KIN-193 on cell proliferation on a large panel of 422 cancer cell lines using high-throughput tumor cell line profiling (18). As shown in Fig. 2A, 35% of cell lines with PTEN mutations (20 out of 57) and 16% of cell lines with wild-type PTEN (58 out of 365) were sensitive to KIN-193 with a threshold of EC50 < 5 µM. The statistical analysis suggested that cell lines harboring mutations in PTEN exhibited significantly higher sensitivity to KIN-193 (p=0.0014, two tailed fisher, Fig. 2A, and Supplementary Table 3). We further evaluated the effect of KIN-193 along with other pan- or isoform-selective PI3K inhibitors on PI3K signaling on a number of PTEN-null cancer cell lines, including HCC70, MDA-MB-468, BT549 and PC3 cell lines (Supplementary Fig. S4). Our results show that both KIN-193 and GDC-0941 significantly inhibited AKT phosphorylation, while PIK-75 and IC87114 had much less effect (Fig. 2B). Taken together, these data suggest that KIN-193 strongly impairs PI3K signaling in PTEN-deficient cancer cells.

Figure 2
Effects of KIN-193 on PTEN-deficient cancer cells. A, Effects of KIN-193 on the proliferation of a panel of 422 cancer cell lines. IC50 values of KIN-193 are ordered from low to high. Pink bars indicate cell lines known to be mutant for PTEN. The subset ...

In order to facilitate in vivo efficacy studies of KIN-193, we performed pharmacokinetic analyses of KIN-193 and found that intraperitoneal (IP) delivery to be the optimal route to achieve robust in vivo exposure (Supplementary Fig. S5A). To determine the pharmacodynamics of KIN-193 in tumors in vivo, we engineered rat fibroblast (Rat1) cells to express both p53DD, a dominant negative mutant of p53 (10), and a constitutively activated myr-p110β (Rat1-CA-p110β) to enable these cells to form xenograft tumors in mice. For comparison, we also generated an isogenic Rat1 cell line expressing p53DD and myr-p110α (Rat1-CA-p110α), which is also tumorigenic in vivo. We introduced Rat1-CA-p110α and Rat1-CA-p110β cells subcutaneously into the contralateral flanks of athymic mice such that tumors driven by activated p110α or p110β would be exposed to identical conditions and that concern about animal-to-animal variability could be eliminated. When tumors reached a volume of ~500 mm3, the tumor-bearing mice received a single IP injection of KIN-193 (10 mg/kg). The plasma concentration of KIN-193 was highest at 1hour post-injection and declined to undetectable levels by 4h (Supplementary Fig. S5B). Concentrations of KIN-193 in both the CA-p110α- and CA-p110β-driven tumors paralleled the plasma concentrations (Fig. 3A). Analyses of tumor lysates harvested at various time points after KIN-193 injection revealed that the phosphorylation of AKT was significantly reduced at 1hour after KIN-193 injection in Rat1-CA-p110β tumors, but remained unchanged in Rat1-CAp110α tumors (Fig. 3A). These in vivo pharmacokinetic and pharmacodynamic properties suggest that KIN-193 holds promise as an effective in vivo p110β-specific inhibitor.

Figure 3
In vivo characterization of the anti-cancer potential of KIN-193. A, Pharmacokinetics and pharmocodynamics of KIN-193 in mice. Concentrations of KIN-193 in tumors (red lines) and relative pAKTT308 phosphorylation values (black columns) in Rat-CA-p110α ...

To evaluate the efficacy of KIN-193 in blocking tumor growth in vivo, we generated additional cohorts of mice bearing tumors driven by Rat1 cell expressing CA-p110α or CA-p110β. When tumors size reached ~500 mm3, these mice were grouped and administered with vehicle control or KIN-193 by IP (20 mg/kg) once or twice daily. While administration of KIN-193 significantly impaired Rat1-CA-p110β-driven tumor growth in a dose-dependent manner, KIN-193 had little effect on the growth of Rat1-CA-p110α-derived xenograft tumors (Fig. 3B), demonstrating the specific anti-tumor effect of KIN-193 on p110β-driven tumors in vivo. Remarkably, all mice receiving KIN-193 either one or two doses daily maintained their body weight throughout the entire treatment course of 13 days (Fig. 3C), indicating that KIN-193 is well tolerated in mice.

We next assessed the anti-tumor activity of KIN-193 on the growth of PTEN-deficient tumors in vivo using cohorts of mice bearing PTEN-deficient tumor xenografts (HCC70 and PC3) and PTEN wild-type tumor xenografts (HCC1954). KIN-193 significantly inhibited tumor growth of both HCC70 and PC3 tumors, but failed to block the growth of HCC1954 tumors (Fig. 4A–C). However, HCC1954, a wild-type PTEN cancer cell line harboring an activated mutant p110α, responded to treatment with the pan-PI3K inhibitor, GDC-0941 (Fig. 4C). Concurrently, immunohistochemistry (IHC) analyses of tumor specimens isolated from tumor-bearing mice at 4 days after treatment revealed that KIN-193 dramatically reduced levels of both AKT phosphorylation and Ki67 signal in xenograft tumors of both PTEN-deficient cancer cell lines, HCC70 and PC3 (Fig. 4D, E). In contrast, a pan-PI3K inhibitor, GDC-0941, but not KIN-193, blocked AKT phosphorylation and cell proliferation in HCC1954 tumor xenografts (Fig. 4F). We conclude that KIN-193, a p110β-selective inhibitor, can specifically suppress both the PI3K pathway activation and oncogenic transformation induced by PTEN-deficiency.

Figure 4
In vivo effect of KIN-193 on PTEN-deficient tumors. A–C, Xenograft tumor growth curves of HCC70, PC3 and HCC1954 treated with vehicle or KIN-193 (IP, 20 mg/kg, BID), or GDC-0941 (PO, 150 mg/kg, QD) (HCC1954 tumors) as indicated. The data are represented ...


Accumulating evidence has suggested that distinct PI3K isoforms are specifically involved in a variety of different disease conditions including cancer, metabolic disorders, immunity and cardiovascular dysfunction (1821). Previous reports have demonstrated that p110β is important in thrombosis and that a selective p110β small molecular inhibitor, TGX-221, prevents platelet aggregation in an extracorporeal circulation model (8). Recently our group and others have provided compelling evidence that p110β is involved in PTEN-loss-induced tumorigenesis (57). Additional aspects of p110 isoform dependency of PTEN-deficient cancer cell lines were presented at the fourth Cold Spring Harbor conference on PTEN Pathways & Targets (22). However, no p110β-specific inhibitors have been described in tumor studies in vivo. Here we demonstrate for the first time that a p110β selective inhibitor, KIN-193, can block both the signaling and tumor growth driven by PTEN loss, providing the first pharmacological evidence for tumor dependence on p110β kinase activity and suggesting that PTEN null tumors would be an appropriate genetic background to deploy these inhibitors. Notably, IC50 values for KIN-193 differ with the system of study, e.g. it is about 1 nM in vitro and 100–500 nM in cell culture (Figure 1A and C). It can reach as high as 1µM in vivo. While enzymatic assays are useful, they are poor predictors of whether bonafide cellular selectivity will be achieved. We demonstrate that in cell culture we can achieve selectivity of p110β over p110α and p110δ (Figure 1A). In mice we have only demonstrated that KIN-193 inhibits the PI3K signaling and tumor growth driven by activated p110β, but not p110α. However as the concentrations in vivo are in the range that other PI3K family members, e.g. p110δ and DNA-PK maybe inhibited, we can not exclude that they contribute to the antiproliferative effects.

The waterfall profiling of cancer cell lines for sensitivity to KIN-193 is particularly interesting for two notions. First, while there is a significant correlation between PTEN mutation and sensitivity to KIN-193, not all PTEN-null cell lines are impacted by treatment with KIN-193. This is perhaps not surprising. Our prior finding of the importance of p110β in PTEN-loss driven tumorignesis was based on a defined genetic mouse model, whereas human cancer lines are far more complex in their genetic makeups. Since loss of PTEN simply removes the “brakes” on the PI3K pathway, the dependence of PTEN-null tumors on p110β maybe altered by co-existing mutations of the tumor. Thus, if PTEN-null tumor cells also harbor a p110α gain-of-function mutation or an upstream mutation that primarily drives p110α activation, then the tumor might be depend on p110α, not p110β. It is also possible that the presence of other oncogenic mutations downstream of PI3K (e.g. AKT) or in PI3K-independent pathways may render PTEN-null tumors less reliant on p110β. Recent studies have demonstrated that p110β signals downstream of certain GPCRs or integrins (5, 23). It also has been proposed that p110β is responsible for the basal lipid kinase activity that can be enhanced in the absence of PTEN to drive transformation (5, 12, 24). Therefore, only those PTEN-null tumors in which the PI3K pathway is activated by certain GPCRs or integrins that drive p110β activation or perhaps via the background PI3K activity contributed by p110β are expected to remain dependent on p110β. The second feature of the profiling is perhaps more interesting. There are a number of the cell lines that respond to KIN-193 that are not PTEN-null by mutation. While some of these lines may have lost PTEN expression by other means, e.g. epigenetic alterations, it is possible that there are PTEN independent mechanisms that activate p110β in tumors.

To date, the array of PI3K inhibitors that are in pre-clinical and clinical development consists largely of pan-inhibitors, and patients with PTEN-deficient tumors are potential candidates for such PI3K-targeted therapy. However, isoform-specific molecules are emerging in the clinic. The promising early clinical results of the p110δ-selective inhibitor CAL-101 in treating lymphoid malignancies suggest that isoform-selective inhibitors may have efficacy and safety advantages over pan-PI3K inhibitors (25). This study identifies KIN-193 as a selective and efficacious p110β inhibitor and demonstrates its potent anti-cancer activity in PTEN-deficient tumor models, providing a starting point from which to develop orally bioavailable compounds that could ultimately be used to assess the potential therapeutic benefit of treating p110β-dependent tumors.


Cell Culture

Cancer cell lines (HCC1954, HCC70, BT549, BT474, and PC3) were obtained from the American Type Culture Collection (Manassa, VA). The MDA-MB-468 cell line was from MD Anderson Cancer Center. These cells were frozen after receiving and freshly thawed cells were used at early passage, and no authentication was done by the authors. These cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 100 µg/ml penicillin-streptomycin. HMEC derivative cell lines were cultured as previously described (10). Rat1 cells and its derived cell lines were maintained in DMEM supplemented with 10% FBS and 100µg/ml penicillin-streptomycin. Rat1 stable cell lines were generated by serial infection with retroviral supernatants carrying p53DD and Myr-HA-p110α or Myr-HA-p110β in the presence of 8µg/ml polybrene. The cells were then selected with blasticidin 5 µg/ml and puromycin 2 µg/ml.

Compounds and Reagents

PIK-75 and TGX-221 were from Chemdea (Ridgewood, NJ). IC87114 was from Selleck Chemicals (Houston, TX). GDC-0941 and KIN compounds were purchased from MedChemexpress (Shanghai, China). Anti-PTEN, anti-p110α, anti-p110β, anti-phospho-AKT (Thr308), anti-phospho-AKT (Ser473), and anti-AKT were all from Cell Signaling Technology (Hanover, MA Anti-p85 antibody was from Upstate Biotechnology (Billerica, MA). Anti-p110δ antibody was from Santa Cruz (Santa Cruz, CA). Anti-vinculin and anti-α-tubulin antibodies were from Sigma (Rockford, IL). Anti-Ki67 antibody was from Vector Labs (Burlingame, ST).

LanthaScreen® Cellular Assay

Experiments were performed according to the manufacturer’s instructions (Invitrogen) and a previous report (16). Briefly, a 10% BacMam GFP-AKT virus (10% v/v) solution was incubated with HMECs overnight with 0.5x Enhancer Solution. The next day, transduced cells were harvested and seeded in a white 384-well plate (Corning #3570) at a density of 5,000 cells/well in 36 µl of Opti-MEM® reduced serum medium. The following day, cells were treated with serial dilutions of compounds (4 µl of 10X solution in 1% DMSO) for 1.5 h. After compound treatment, the assay medium was removed and cells were lysed via the addition of LanthaScreen® lysis buffer in 20 µl volume supplemented with protease and phosphatase inhibitor cocktails and either Tb-anti-pAKTT308 or Tb-anti-pAKTS473 antibody (2 nM final concentration) for 2 h at room temperature. The TR-FRET signal (Emission Ratio 520 nm/495 nm) was read on an EnVision® fluorescence plate reader from PerkinElmer (Waltham, MA). Compounds were tested in duplicate and the data presented is from at least 2 independent experiments. Curve fitting analysis and IC50 value determination was performed using GraphPad Prism 4.

Ambit in vitro KinomeScan™ Kinase Selectivity Profile

KIN-193 was profiled at a concentration of 10 µM against a diverse panel of 433 kinases by Ambit Biosciences. Scores for primary screen hits are reported as percent of the DMSO control (% control). For kinases where no score is shown, no measurable binding was detected. The lower the score, the lower the Kd is likely to be, such that scores of zero represent strong hits. Scores are related to the probability of a hit, but are not strictly an affinity measurement. At a screening concentration of 10 µM, a score of less than 10% implies that the false positive probability is less than 20% and the Kd is most likely less than 1 µM. A score between 1– 10% implies that the false positive probability is less than 10%, although it is difficult to assign a quantitative affinity from a single-point primary screen. A score of less than 1% implies that the false positive probability is less than 5% and the Kd is most likely less than 1 µM.

High-throughput Cell Viability Assay

Cell viability was determined as previously described (18). Briefly, cells were seeded in medium containing 5% FBS at a density insuring cell growth throughout drug treatment (~15% for most cell lines). Drug treatment was started 24 h post seeding and continued for 72 h. Cell were fixed and stained using Syto60 (Invitrogen), a red fluorescent DNA stain. The relative cell number was calculated by taking the ratio of the relative fluorescence intensity from drug treated wells over untreated wells after background subtraction (cells-free wells). Nine doses of KIN-193 were used in 2-fold dilution steps ranging from 5.12 µM to 0.02 µM. IC50, corresponding to 50% cell number compared to control (untreated) wells, was determined using a fixed top and bottom sigmoidal fitting algorithm implemented in PipelinePilot (Accelerys).

Western Blot Analysis

Tumor samples or cells were lysed in ice-cold RIPA buffer (1% NP40, 0.1% SDS, 0.5% sodium deoxycholate in 1X PBS) containing protease inhibitor cocktail (Roche) and phosphatase inhibitor (Thermo) and lysates were clarified by centrifugation. For experiments with compound treatments, the 80% confluent cells in 6-well plates were treated with the indicated compound for one hour, then the cells were lysed in SDS loading/lysis buffer (4% SDS, 20% glycerol, 120 mM Tris pH6.8, and pyronin Y). Equal amount of lysates were resolved on SDS-PAGE gels and transferred to nitrocellulose membranes. After incubation with blocking buffer (50% LICOR blocking buffer in PBS) for 1h, the membranes were incubated with primary antibody overnight at 4 °C, and then incubated with fluorescently-labeled secondary antibodies (Rockland Immunochemicals) for 1 h at room temperature. The protein signal was detected using an Odyssey scanner (LI-COR, Lincoln, NE).

In vivo Pharmacokinetics and Pharmocodynamic Assays

Approximately 6–8 week-old female nude mice (Taconic) were injected s.c. with Rat1-Myr-HA-p110α(Rat1-CAp110α) cells (1×106 cells in 40% matrigel) (BD Biosciences, San Jose, CA) in one flank (site 1) and Rat1-Myr-HA-p110β (Rat1-CAp110β) cells (0.5×106 cells in 10% matrigel) in the contralateral flank (site 2). When tumors grew to ~500 mm3, mice were dosed once by ip injection with KIN-193 formulated in 7.5% NMP (Sigma), 40% PEG400 (Sigma), 52.5% dH20 at 0.1 ml/10g body weight and 10 mg/kg. Tumors were collected at 0, 1, 4, 8, and 24 h following compound administration and blood samples were obtained by direct heart puncture. Serum was separated and stored at −80°C. The drug concentrations in serum and tumor samples were assessed by LC-MS/MS analysis by the DMPK group at Scripps, Florida. The phosphorylation status of AKT in tumor samples was assessed by Western blot analysis and quantified using ImageJ software with statistical calculations performed using Prism software.

Xenograft Tumor Growth

Each flank of athymic nude mice was injected s.c. with 1×106 cells resuspended in 30% matrigel. KIN-193 was given ip either once or twice a day at 20 mg/kg. GDC-0941 (0.1% methylose, 0.1% Tween 80) was given by gavage at 150 mg/kg once per day. Rat1-CA-p110α, Rat1-CA-p110β, HCC70 and HCC1954 xenograft tumor growth was assessed in female nude mice. PC3 xenograft tumor growth was assessed in male nude mice. Tumor bearing animals were treated with KIN-193, GDC-0941 or vehicle control as described above. Tumor volumes were calculated using the formula (length × width2)/2. All the animal experiments were done in accordance with NIH animal use guidelines and protocols approved by the Dana-Farber Cancer Institute Animal Care and Use Committee.

Immunohistochemical Staining

Deparaffinized tissue sections were heated in 10 mM sodium citrate buffer for 20 min using a microwave oven. Primary antibodies were incubated on slides overnight at 4°C. Sections were then incubated with biotinylated secondary antibody (Vector Labs, CA) and ABC solution (Vector Labs, CA). Tissues were stained by DAB (Vector Labs, CA), followed by Meyer’s hematoxylin counterstaining (BioGenex Laboratories, CA).


We report the first functional characterization of a p110β-selective inhibitor, KIN-193, that is efficacious as an anti-tumor agent in mice. We demonstrate that this class of inhibitor holds great promise as pharmacological agent that could be used to address the potential therapeutic benefit of treating p110β-dependent PTEN-deficient human tumors.

Supplementary Material

Supplemental Data 2

Supplemental Data 3


We thank Dr. Roderick Bronson and the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core for histopathological analyses. This work was supported by NIH grants CA030002 (TMR), and CA134502 (JJZ), P50CA089393-08S1 (JJZ), CA148164-01 (JJZ, NSG, ME and TMR), 1U54HG006097-01 (CHB). Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (SU2C-AACR-DT0209) (TMR and JJZ). In compliance with Harvard Medical School guidelines, we disclose that TMR and JJZ are consultants for Novartis Pharmaceuticals, Inc.


Disclosure of Potential Conflicts of interest

The authors declare no potential conflicts of interest.


1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. [PubMed]
2. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627–644. [PMC free article] [PubMed]
3. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007;12:104–107. [PubMed]
4. Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009;69:3955–3962. [PMC free article] [PubMed]
5. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 [PMC free article] [PubMed]
6. Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008;105:13057–13062. [PubMed]
7. Torbett NE, Luna-Moran A, Knight ZA, et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008;415:97–110. [PMC free article] [PubMed]
8. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507–514. [PubMed]
9. Zhao JJ, Gjoerup OV, Subramanian RR, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003;3:483–495. [PubMed]
10. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102:18443–18448. [PubMed]
11. Sun M, Hart JR, Hillmann P, Gymnopoulos M, Vogt PK. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110alpha of phosphoinositide-3-kinase. Cell Cycle. 2011;10:3731–3739. [PMC free article] [PubMed]
12. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733–747. [PMC free article] [PubMed]
13. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005;106:1063–1066. [PubMed]
14. Raynaud FI, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009;8:1725–1738. [PMC free article] [PubMed]
15. Lempiainen H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009;28:3067–3073. [PubMed]
16. Carlson CB, Mashock MJ, Bi K. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds. J Biomol Screen. 2010;15:327–334. [PubMed]
17. Fjellstroem OG, David Jackson, Shaun Lundberg, Jan Aa. Preparation of enantiomerically pure (−)2-[1-(7-Me-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use as a selective PI 3-kinase β inhibitor for therapy. PCT Int. 2009
18. McDermott U, Sharma SV, Dowell L, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007;104:19936–19941. [PubMed]
19. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737–749. [PubMed]
20. Sopasakis VR, Liu P, Suzuki R, et al. Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab. 2010;11:220–230. [PMC free article] [PubMed]
21. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3:317–330. [PubMed]
22. Brachmann SM, Herkert B, Kauffmann A, et al. PIKing the right isoform in PTEN deficient cancers: targeting p110beta?; Cold Spring Harbor Laboratory Annual Meeting, PTEN pathway & Targets; 2012.
23. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110{beta} isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110{gamma} Proc Natl Acad Sci U S A. 2008 [PubMed]
24. Dbouk HA, Pang H, Fiser A, Backer JM. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2010;107:19897–19902. [PubMed]
25. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603–3612. [PubMed]